SEC Filings
Autolus AUCATZYL Sales Surge 95% — Its Annual Outlook Now Reaches The Former Ceiling
Manufacturing margins improved, but the company moved its first multiple-sclerosis data presentation to October 2027.
SEC Filings
Manufacturing margins improved, but the company moved its first multiple-sclerosis data presentation to October 2027.
SEC Filings
A Genevant dividend helped produce a quarterly profit, while Arbutus paid $230 million to repurchase shares in early October.
SEC Filings
Adjusted EBITDA rose for a fifth consecutive quarter, while Liquidia faces $380.7 million in net settlement payments.
SEC Filings
The institutional holder reported 2,469,425 common shares in a disclosure covering September 30, 2026.
SEC Filings
The holding covered September 30, 2026, and included shared voting authority over 2,490,708 shares.
SEC Filings
Research expenses rose to $67.6 million as Olema funded breast-cancer trials and prepared for potential commercialization.
SEC Filings
The September-end position covered 3,595,632 common shares and was held through ordinary business activity.
SEC Filings
The holding covered 12,294,412 shares, while BioCryst raised its revenue outlook and pulled back from internal research.
SEC Filings
Research spending rose to $36.6 million as verekitug moved toward pivotal asthma and nasal-polyp trials.
SEC Filings
The reported holding covered 7,570,589 shares, with shared voting authority over 4,863,692.
SEC Filings
Taiho's lung-cancer combination application is now expected to be completed in November, rather than by year-end.
SEC Filings
The passive holding covered September 30, while the current-quarter earnings estimate fell to $1.70 per share from $1.78.